INVO Fertility (IVF) Corporate presentation summary

Mission and strategy

• Focused on making advanced fertility care effective, accessible, and empowering through innovation and a patient-centered approach.

• Evolved from a device company to a comprehensive fertility healthcare provider, now operating four clinics and pursuing M&A for growth.

• Strategic shift includes divesting non-core assets, rebranding, and strengthening operational leadership.

• Growth driven by acquiring profitable clinics, expanding organic initiatives, and leveraging proprietary technology.

• Targeting secondary U.S. markets with supply-demand imbalances and integrating ancillary fertility services.

Market opportunity

• U.S. IVF market estimated at $5.7B in 2023, with a projected 5.1% CAGR through 2030.

• Approximately 1 in 6 people globally experience infertility, driving demand for ART.

• Policy momentum and demographic trends support increased access and affordability.

• Clinic landscape is fragmented, with consolidation opportunities for growth.

Technology and innovation

• INVOcell device enables in vivo fertilization and embryo incubation, improving efficiency and patient experience.

• New patent extends INVOcell protection through 2040, reinforcing a defensible platform.

• Telehealth and time-lapse incubation technologies implemented to expand access and enhance monitoring.

• INVOcell clinical pregnancy rates (~57.1%) are comparable to IVF and superior to IUI.